Award Number: W81XWH-09-1-0128

TITLE: Imaging CXCL12-CXCR4 Signaling and Inhibition in Ovarian Cancer

PRINCIPAL INVESTIGATOR: Gary Luker

CONTRACTING ORGANIZATION: University of Michigan
Ann Arbor, MI 481091274

REPORT DATE: October 2013

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
# Imaging CXCL12-CXCR4 Signaling and Inhibition in Ovarian Cancer

## Abstract
CXCR4 and its chemokine ligand CXCL12 are potential targets for molecular therapy of ovarian cancer. Receptor CXCR4 is expressed by ovarian cancer cells in approximately 50% of patients. High levels of CXCL12 are present in ascites of patients with ovarian cancer, providing a local source of chemokine ligand in the tumor microenvironment. CXCL12 signaling through CXCR4 activates pathways that could promote tumor growth, invasion, metastasis, and resistance to chemotherapy. To advance clinical translation of CXCR4 inhibitors for therapy of ovarian cancer, we developed molecular imaging reporters for CXCR4 signaling that can be used for cell-based assays and real-time imaging studies in mouse xenograft models of ovarian cancer. After validating that these reporters correspond with biochemical measures of CXCL12-CXCR4 signaling, we used optical imaging to quantify pharmacodynamics of therapy for CXCR4 targeted inhibitors in mice with ovarian cancer. Treatment studies established that inhibiting CXCR4 prolonged survival of mice with ovarian cancer and potentially could improve treatment efficacy of a standard chemotherapeutic drug, cisplatin.

## Subject Terms
- Optical imaging, chemokine, chemokine receptor, signal transduction

## Security Classification
- **a. REPORT**: U
- **b. ABSTRACT**: U
- **c. THIS PAGE**: U
- **19a. NAME OF RESPONSIBLE PERSON**: USAMRMC
- **19b. TELEPHONE NUMBER**: (include area code)

**12. DISTRIBUTION / AVAILABILITY STATEMENT**
Approved for Public Release; Distribution Unlimited
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Body</td>
<td>1</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>3</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>3</td>
</tr>
<tr>
<td>Conclusion</td>
<td>3</td>
</tr>
<tr>
<td>References</td>
<td>3</td>
</tr>
<tr>
<td>Appendices</td>
<td>4</td>
</tr>
</tbody>
</table>
Imaging CXCL12-CXCR4 Signaling and Inhibition in Ovarian Cancer

1. Introduction. CXCR4 and its chemokine ligand CXCL12 are potential targets for molecular therapy of ovarian cancer. Receptor CXCR4 is expressed by ovarian cancer cells in approximately 50% of patients. High levels of CXCL12 are present in ascites of patients with ovarian cancer, providing a local source of chemokine ligand in the tumor microenvironment. CXCL12 signaling through CXCR4 activates pathways that could promote tumor growth, invasion, metastasis, and resistance to chemotherapy. To develop CXCL12-CXCR4 as molecular targets for chemotherapy in ovarian cancer, there is an unmet clinical need to understand how these signaling pathways function in the tumor microenvironment of ovarian cancer in vivo. In this research, we developed new molecular imaging technologies and signaling reporters to analyze CXCR4 signaling in vivo and determined to what extent inhibiting CXCL12-CXCR4 signaling alters disease progression in mouse models of ovarian cancer.

2. Body.

Aim 1. To construct ovarian cancer cell lines with molecular imaging reporters to quantify activation of CXCR4 and downstream effector molecules.

A. Time period: Months 1-16

B. Tasks to be completed:
1. Establish ovarian cancer cell lines (Hey-8, Skov3i.p.1) stably expressing CXCR4 imaging reporters for receptor homodimerization, recruitment of β-arrestin 2, and activation of AKT.
2. Test responses of each reporter cell line to stimulation with CXCL12 and inhibition with CXCR4 inhibitors AMD3100 and TF1403 in cell-based assays.
3. Test CXCL12-dependent activation of signaling pathways in reporter cells using biochemical assays including Western blotting.

Progress. 1. We established Hey-8 cell lines with these reporters except for the AKT construct. We designed and tested different reporter constructs for AKT activity, but none generated specific signals for this pathway in cell based assays. Dimerization reporters showed substantially slower kinetics of response to CXCL12 or targeted inhibitors (see Luker, FASEB J, 2009 for work on these reporters not funded by this project); this reporter also did not provide unique therapeutic opportunities as compared with the CXCR4-β-arrestin 2 reporter. Performance of our imaging reporters in terms of signal to background was notably better for Hey-8 cells than Skov3i.p.1, so our experiments in cell culture and animals were performed with the Hey-8 cell line and the CXCR4-β-arrestin 2 reporter (Fig 1).

2. In cell-based assays with stably transduced reporter cells, we demonstrated that these reporter cells generate bioluminescence in response to CXCL12 (β-arrestin reporter, Fig 2). We focused on treatment studies with AMD3100, the only FDA-approved inhibitor of CXCL12 binding to CXCR4. As shown in Fig 2, AMD3100 blocked CXCL12-dependent activation of the CXCR4-β-arrestin 2 reporter. These data further establish specificity of the imaging reporter for rapid responses to CXCR4 signaling and inhibition with a clinically-approved drug.

3. We validated expression of reporter cells and activation of downstream signaling by Western blot and flow cytometry. Western blotting showed that Hey-8 reporter cells activated ERK1/2,
kinases known to be activated by CXCL12-CXCR4 signaling. AMD3100 blocked activation of ERK1/2 by CXCL12 in these cells (Fig 3). The reporter cells also activated AKT, another effector of CXCL12-CXCR4 signaling. Western blotting confirmed expression of the β-arrestin 2 fusion to the C-terminal luciferase fragment. Using flow cytometry, we established that cells used for imaging studies express CXCR4 at the cell surface. To reproduce secretion of CXCL12 by ovarian cancer cells in patients, we generated Hey-8 cells expressing CXCL12 fused to Gaussia luciferase. We previously demonstrated that the CXCL12-Gaussia luciferase fusion protein activates CXCR4 signaling. As controls, we used lentiviruses to produce Hey-8 cells expressing full length luciferase and unfused Gaussia luciferase, respectively. These data verify that the reporter cells signal appropriately in response to CXCL12

**Aim 2. Image and quantify activation of CXCR4 signaling and pharmacodynamics of CXCR4 inhibitors in mouse models of ovarian cancer.**

**A. Time period:** Months 13-36

**B. Tasks to be completed:**

1. Establish intraperitoneal ovarian cancer xenografts of Hey-8 or Skov3.i.p. cells stably expressing CXCR4 imaging reporters. Xenografts will be established in Ncr<sup>nu/nu</sup> (nude) mice.
2. Perform bioluminescence imaging and MRI studies of CXCR4 signaling and tumor progression.
3. Quantify inhibition of CXCR4 signaling with known and candidate CXCR4 inhibitors and establish to what extent inhibition of CXCR4 signaling correlates with tumor growth and overall survival.

**Progress.** 1. We used SCID mice rather than Ncr<sup>nu/nu</sup> (nude) mice because the former strain had more reliable take and growth of Hey-8 tumor xenografts. For reasons described above, we did not accomplish imaging studies with Skov3.i.p. cells.

2. Since motion artifact degraded severely degraded image quality and precluded detection of intraperitoneal ovarian tumors, we stably expressed a far red fluorescent protein (eqFP650) in Hey-8 cells expressing the CXCR4-β-arrestin 2 reporter and used fluorescence imaging to monitor tumor growth. We also used bioluminescence imaging to detect cells expressing CXCL12-Gaussia luciferase. These methods allowed us to image overall tumor burden in mice and use bioluminescence imaging for luciferase to monitor CXCR4 signaling. Treatment with AMD3100 inhibited CXCR4 signaling in vivo, allowing us to monitor pharmacodynamics of therapy.

3. We treated mice with established Hey-8 reporter cell xenografts for two weeks with AMD3100 delivered via implanted osmotic infusion pumps. Control mice received vehicle control delivered by osmotic infusion pump. AMD3100 blocked CXCR4 signaling, delayed tumor growth, and prolonged overall survival of treated mice (Fig 5). We also treated mice with AMD3100 alone, cisplatin (a standard chemotherapeutic drug for ovarian cancer), or both agents. Combination treatment with AMD3100 and cisplatin produced a trend toward greater survival, but the effect was not significant (Fig 5). Due to challenges of managing toxicity of cisplatin in mice and delivering AMD3100, we only treated mice with this drug combination for two weeks. With better supportive care such as that available to patients, it may be possible to extend treatment longer and achieve significant gains in overall survival in mice treated with
both AMD3100 and cisplatin. Overall, these data show that treatment with AMD3100 modestly extends survival of mice with human ovarian cancer xenografts.

**Key Research Accomplishments.**
- Established that AMD3100 blocks CXCL12-dependent recruitment of β-arrestin 2 during extended periods of therapy in a mouse xenograft model.
- Showed that treatment with AMD3100 improved overall survival of mice with intraperitoneal metastases of ovarian cancer.
- Found a trend toward improved survival of mice treated with combination therapy of AMD3100 to block CXCL12-CXCR4 and the standard chemotherapeutic drug cisplatin.

**Reportable Outcomes for the Project.**
- Cells: Hey-8 ovarian cancer cells expressing CXCL12 fused to Gaussia luciferase or expressing eqFP650 for fluorescence imaging.
- Cells: Hey-8 ovarian cancer cells expressing luciferase complementation reporters for CXCR4 signaling to β-arrestin 2.

**Conclusion.** Our research established imaging reporters for activation of CXCR4 signaling. We established the ability to monitor activation and inhibition of CXCR4 signaling in real time in cell-based assays and living mice. We also established that treatment with AMD3100 extended survival of mice with Hey-8 ovarian cancer xenografts.

Our research demonstrated a trend toward improved survival in tumor-bearing mice treated with cisplatin, a standard chemotherapeutic drug for ovarian cancer, and AMD3100. This trend was evident even though mice were treated with these drugs for only two weeks, which represents less than one-third of the total observation period. The limited duration of treatment is due to the challenges of administering multi-agent chemotherapy to mice and managing toxicities of therapy. With more advanced methods of medical monitoring and support available to human patients with ovarian cancer, it may be feasible to continue combination therapy over longer periods of time and establish significant improvements in survival.

**References**
Supporting Data

**Fig 1. Schematic of CXCR4 and β-arrestin 2 imaging reporter.** Recruitment of β-arrestin to CXCR4. CXCR4 and β-arrestin 2 were fused to amino (N)- and carboxy (C)-terminal fragments of luciferase, respectively. CXCL12 activates CXCR4 signaling, resulting in recruitment of β-arrestin 2 and reconstitution of luciferase enzymes to produce light (see attached manuscript from PLoS One).

**Fig 2. CXCL12-dependent activation of CXCR4-β-arrestin 2 imaging reporter.** Left) Hey-8 cells expressing the CXCR4-β-arrestin 2 imaging reporter were incubated with 100 ng/ml CXCL12 along with vehicle control or 1 μM of the CXCR4 inhibitor AMD3100 for 240 minutes. Graph shows mean values ± SEM for bioluminescence relative to untreated cells at time = 0. *, p < 0.05; **, p < 0.01. Right) Reporter cells were treated with increasing concentrations of CXCL12 with vehicle control or AMD3100 for 60 minutes. Data were graphed as described for the left panel. Overall data show time-and dose-dependent activation of the imaging reporter.
Fig 3. **Reporter cells signal in response to CXCL12.** Upper left) Cells were incubated with 100 ng/ml CXCL12 for indicated periods to time in the presence of vehicle control or 1 µM AMD3100. Western blot shows activation of ERK1/2 (P-ERK) with total ERK shown as a loading control. We also probed cells for expression of the reporter fusion protein (β-arrestin 2-CBC). The antibody also detects endogenous β-arrestin 2. GAPDH is shown as an additional loading control. Bottom left) Cells were incubated with increasing concentrations of CXCL12 for 10 minutes. Blot shows activation of AKT (pAKT) with total AKT shown as a control for loading of the gel. Upper right) Flow cytometry for cell surface CXCR4 using a monoclonal antibody 12G5 in indicated cell lines. Solid lines denote isotype control antibody, while dashed lines show anti-CXCR4 staining.
Fig 4. Imaging Hey-8 xenografts and effects of AMD3100. Mice were implanted with Hey-8 CXCR4-β-arrestin 2 reporter cells (that co-express eqFP650) and Hey-8 cells expressing CXCL12 fused to Gaussia luciferase by intraperitoneal injection. Fluorescence imaging (upper left) and bioluminescence imaging for Gaussia luciferase (upper right) enable monitoring of tumor growth. Lower left) Luciferase complementation images for CXCR4 interaction with β-arrestin 2 in mice before and six days after treatment with AMD3100. Lower right) Quantified data (mean + SEM) for luciferase complementation bioluminescence normalized to fluorescence from eqFP650. AMD3100 inhibited CXCR4 signaling, as evidenced by significantly lower imaging signal (*, p < 0.05).
Fig 5. AMD3100 extends survival of mice with Hey-8 reporter cell xenografts. Upper left) Fluorescence imaging for eqFP650 (mean values + SEM) show that AMD3100 significantly reduces overall tumor growth of Hey-8 cells (*, P < 0.05). Data were normalized to fluorescence from each mouse on day 0 to account for animal-to-animal variations in tumor burden prior to therapy. Upper right) Kaplan-Meier curves for survival of mice treated with AMD3100 or vehicle control (PBS). Arrow denotes start of therapy. Lower left) Area under the curve analysis of imaging data for CXCR4-β-arrestin 2 signaling normalized to total tumor burden (FP650 fluorescence) shows that AMD3100 or AMD3100 plus cis-platin treatment reduces CXCR4 signaling in vivo. Lower right) Kaplan-Meier curves show a trend for greater survival in mice treated with AMD3100 and cisplatin.
Imaging CXCL12-CXCR4 Signaling in Ovarian Cancer Therapy

Emma Salomonnson1, Amanda C. Stacer1, Anna Ehrlich1, Kathryn E. Luker1, Gary D. Luker1,2,3,*

1 Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America, 2 Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America, 3 Department of Biomedical Engineering, University of Michigan Medical School, Ann Arbor, Michigan, United States of America

Abstract

Chemokine CXCL12 and receptor CXCR4 have emerged as promising therapeutic targets for ovarian cancer, a disease that continues to have a dismal prognosis. CXCL12-CXCR4 signaling drives proliferation, survival, and invasion of ovarian cancer cells, leading to tumor growth and metastasis. Pleiotropic effects of CXCR4 in multiple key steps in ovarian cancer suggest that blocking this pathway will improve outcomes for patients with this disease. To quantify CXCL12-CXCR4 signaling in cell-based assays and living mouse models of ovarian cancer, we developed a click beetle red luciferase complementation reporter that detects activation of CXCR4 based on recruitment of the cytosolic adapter protein β-arrestin 2. Both in two-dimensional and three-dimensional cell cultures, we established that bioluminescence from this reporter measures CXCL12-dependent activation of CXCR4 and inhibition of this pathway with AMD3100, a clinically-approved small molecule that blocks CXCL12-CXCR4 binding. We used this imaging system to quantify CXCL12-CXCR4 signaling in a mouse model of metastatic ovarian cancer and showed that treatment with AMD3100 interrupted this pathway in vivo. Combination therapy with AMD3100 and cisplatin significantly decreased tumor burden in mice, although differences in overall survival were not significantly greater than treatment with either agent as monotherapy. These studies establish a molecular imaging reporter system for analyzing CXCL12-CXCR4 signaling in ovarian cancer, which can be used to investigate biology and therapeutic targeting of this pathway in cell-based assays and living mice.

Introduction

Chemokine CXCL12 (SDF-1) and its receptor CXCR4 are strongly implicated as key determinants of tumor initiation and intraperitoneal metastasis of ovarian cancer [1]. CXCL12 is secreted by ≈70–90% of ovarian cancer cells, as well as mesothelial cells within the peritoneum of humans and mice [2] [3] [4] [5]. Patients with the highest levels of CXCL12 expression in ovarian cancer cells have a significantly worse prognosis, emphasizing the biologic significance of this signaling molecule in disease progression [6]. Effects of CXCL12 on ovarian cancer appear to be mediated by CXCR4, one of two known receptors for this chemokine. Amplification of CXCR4 is an early event in malignant transformation of ovarian epithelial cells, suggesting that CXCL12-CXCR4 is critical for pathogenesis of this disease [7]. Approximately 60% of patients with ovarian cancer have CXCR4 on malignant cells, and these patients have significantly reduced overall survival [4]. CXCL12 signaling through CXCR4 promotes proliferation, invasion, and metastasis of ovarian cancer cells, all of which contribute to more aggressive disease. Adverse effects of CXCL12 on ovarian cancer also may be due to effects on the stromal compartment of the tumor microenvironment, including enhanced angiogenesis and recruitment of immunosuppressive cells [8] [9] [10] [11].

Central functions of CXCL12-CXCR4 signaling in malignant cells and the tumor microenvironment position this signaling axis as a key target to improve therapy for patients with ovarian cancer. In mouse models, we and others have shown that blocking CXCL12-CXCR4 signaling with RNA interference against CXCL12 or a small molecule inhibitor of CXCL12-CXCR4 binding (AMD3100) limits growth of ovarian cancer cell implants [12,13,14]. Inhibiting CXCL12-CXCR4 signaling also extends survival of mice with ovarian cancer. However, effects of single agent therapy are modest, suggesting that targeting CXCL12-CXCR4 in combination with another agent may be more beneficial. Establishing that a compound effectively hits its intended target is essential for drug development in pre-clinical models and clinical trials. To analyze pharmacodynamics of agents targeting CXCL12-CXCR4 signaling in mouse models of ovarian cancer, we developed a click beetle luciferase complementation reporter to image and quantify activation and inhibition of this pathway in vivo. In this system, CXCR4 and the cytosolic adapter protein β-arrestin 2 are fused to inactive amino (CBRN) and carboxy (CBC) terminal fragments of click beetle red luciferase. The reporter measures CXCL12 activation of CXCR4 signaling based on recruitment of the cytosolic adapter protein β-arrestin 2 to this receptor. Recruitment of β-arrestin 2 is a common, early event in activation of chemokine receptors and the larger family of seven
transmembrane receptors [15]. With the luciferase complementation system, interactions between CXCR4 and β-arrestin 2 reconstitute active click beetle luciferase to produce light, providing an imaging metric for CXCR4 signaling in intact cells, three-dimensional spheroid cultures, and living mice. Spheroids are an important intermediate between standard two-dimensional cell culture assays and tumor xenografts since tumor spheroids reproduce restricted diffusion of compounds in tumors and formation of ovarian cancer spheroids in ascitic fluid from patients. Since luciferase complementation is reversible, this imaging reporter also can be used to measure effects of compounds blocking CXCL12-CXCR4 signaling in vitro and in vivo.

We used this imaging reporter to analyze CXCL12-CXCR4 signaling in ovarian cancer and establish that AMD3100, a small molecule inhibitor of CXCR4, blocks receptor activation in the tumor microenvironment. Using this imaging system, we determined that combination therapy with AMD3100 and cisplatin significantly decreased overall tumor burden in a mouse model of human ovarian cancer with intraperitoneal metastases. These results establish a new molecular imaging method to analyze CXCL12-CXCR4 signaling in ovarian cancer and suggest possible therapeutic benefit of combining selective inhibition of this chemokine receptor pathway with standard chemotherapeutic drugs.

Materials and Methods

Plasmids

To generate fusions of CXCR4 with the N-terminal fragment of click beetle red luciferase (CBRN) (Promega), we amplified CXCR4 by PCR and cloned the product into the XhoI and AgeI sites of EGFP-N1 (Clontech). We used PCR to amplify the DNA sequence for amino acids 2–413 of click beetle red luciferase (CBRN) and cloned this product into AgeI and NotI sites of EGFP-N1 [16]. This cloning strategy removes EGFP from the vector. We amplified the sequence for amino acids 395–542 of click beetle luciferase (CBC) by PCR and cloned the product into the AgeI and NotI sites of EGFP-N1 to create a fusion to the C-terminus of β-arrestin 2 (gift of Robert Lefkowitz). To transfer constructs from the EGFP-N1 backbone to lentiviral vector FUV, we used PCR to amplify the target DNA sequence and add XbaI sites for cloning. Constructs used for this study are summarized in Table 1 (Fig. 1A), and PCR primers used for cloning are listed in Table 1.

Cells

HeyA8 ovarian cancer cells (provided by Gordon Mills, MD Anderson Cancer Center) were stably transduced with recombinant lentiviruses for CXCR4-CBRN and Ar-CBC (HeyA8-CXCR4-CBRN/Ar-CBC) [17]. We used lentiviral transduction to establish populations of HeyA8 cells stably expressing CXCL12 fused to Gaussia luciferase (HeyA8-CXCL12-GL), unfused Gaussia luciferase (Hey-GL), and firefly luciferase and green fluorescent protein (GFP) (HeyA8-FL/GFP) [18,19]. We also transduced HeyA8-CXCR4-CBRN/Ar-CBC and HeyA8-CXCL12-GL cells with fluorescent protein eqFP650 [20]. Figure 1 shows a list of stably transduced cells used in this study (Fig. 1A). All cells were maintained in DMEM with 10% fetal bovine serum, 1% glutamine, and 0.1% penicillin/streptomycin.

Flow cytometry

Intact cells were stained with an antibody to CXCR4 (clone 12G5, R&D Systems) or matched isotype control as described previously to reveal cell surface levels of this receptor [21]. Unstained cells from each cell population were used as compensation controls for flow cytometry.

Western blotting

Cells were cultured in medium containing 1% serum overnight and then stimulated for 10 minutes with various concentrations of recombinant CXCL12-α (R&D Systems) for activation of AKT. To determine CXCL12-dependent activation of ERK1/2, we treated serum-starved cells with 100 ng/ml CXCL12-α for 0, 5, 15, or 30 minutes in the presence of vehicle control or 1 μM AMD3100, a small molecule inhibitor of CXCR4 (Tocris). Cell lysates were blotted for phosphorylated AKT or phosphorylated ERK1/2 (Cell Signaling) as described previously [19]. Blots were stripped and re-probed for total AKT or total ERK1/2 as a loading control. We also used Western blotting to determine expression of endogenous β-arrestin 2 and β-arrestin 2-CBC in HeyA8-CXCR4-CBRN/Ar-CBC cells (Cell Signaling). Membranes were stripped an additional time and re-probed for glyceraldehyde phosphate dehydrogenase (GAPDH) as a further loading control. We measured intensities of bands with ImageJ and divided values for phosphorylated AKT by total AKT and GAPDH. We performed similar calculations for phosphorylated ERK relative to total ERK and GAPDH. For both phosphorylated AKT and ERK, we normalized all values to cells not treated with CXCL12.

Two dimensional cell culture experiments

We plated 1.5×10⁴ HeyA8-CXCR4-CBRN/Ar-CBC cells per well in black wall 96 well plates one day before assays. We changed medium from standard culture medium to DMEM with 1% serum for experiments. We incubated cells for increasing periods of time with 100 ng/ml CXCL12-α (R&D Systems) or for 60 minutes with increasing concentrations of chemokine. In selected experiments, cells were incubated with AMD3100 to inhibit CXCL12 binding to CXCR4 or vehicle control at concentrations listed in figure legends. We added 150 μg/ml luciferin (Promega) to wells and then quantified bioluminescence from living cells using an IVIS 100 (Perkin Elmer). Bioluminescence from click beetle luciferase was quantified as described previously and normalized to total protein per well quantified by sulforhodamine B staining [19]. Data were expressed as mean values ± SEM for luminescence relative to untreated controls.

Spheroids

Spheroids were formed in 384-well hanging drop plates by seeding a total of 2×10⁵ HeyA8 cells per well [22]. We used two different types of spheroids: 1) HeyA8-CXCR4-CBRN/Ar-CBC cells mixed with equal numbers of HeyA8-CXCL12-GL cells to assay activation and inhibition of CXCR4 signaling; or 2) HeyA8-FL/GFP cells combined with equal numbers of either HeyA8-CXCL12-GL or HeyA8-GL cells, respectively, for assays of cell viability in response to cisplatin. For experiments with AMD3100, increasing concentrations of compound were added to spheroids one day after seeding in hanging drop plates. We incubated spheroids with AMD3100 or vehicle for one or two days before quantifying bioluminescence. HeyA8-FL/GFP cells in spheroids with either HeyA8-CXCL12-GL or HeyA8-GL cells were treated for one or two days with increasing concentrations of cisplatin. We quantified fluorescence from eqFP650 on an IVIS Spectrum prior to quantifying bioluminescence after adding 6 μg/ml luciferin to each spheroid. We normalized bioluminescence photon flux to fluorescence radiance to account for differences in cell numbers.
Animal studies

All animal procedures were approved by the University of Michigan Committee for the Use and Care of Animals. Animals were switched to chlorophyll-free chow (Research Diets) for all studies to minimize background fluorescence in imaging studies. 2.5×10^5 cells each of HeyA8-CXCR4-CBRN/Ar-CBC and HeyA8-CXCL12-GL cells were injected intraperitoneally in 100 μl 0.9% NaCl into 5–7 week old female NOD/SCID IL2r^−/+ female mice (Taconic). To inhibit CXCL12 binding to CXCR4, we used 5-day, 1.0 ml/hour osmotic pumps (for the experiment shown in Fig. 5) or 14-day, 0.5 ml/hour osmotic pumps (for the experiment shown in Fig. 6) (Alzet) loaded with 25 mg/ml AMD3100 or 0.9% NaCl vehicle control. These pumps deliver 1.25 or 0.625 mg AMD3100/g/hour to each mouse. Pumps were implanted at times indicated in the text for each figure. For treatment studies shown in Figure 6, we injected mice with 4 mg/kg cisplatin or matched vehicle i.p. every 5 days. Cisplatin or PBS vehicle injections continued throughout the two-week period that osmotic infusion pumps were in place. All mice received active compound (AMD3100 and/or cisplatin) or matched vehicle for both routes of delivery (osmotic infusion pump and i.p. injection). As examples, vehicle control mice received osmotic pumps with 0.9% NaCl and i.p. injections of PBS, while mice in the AMD3100 treatment group had osmotic pumps with AMD3100 and i.p. PBS.

Mouse imaging

Bioluminescence imaging was performed on an IVIS Spectrum (Perkin Elmer). Fluorescence imaging and beetle luciferase imaging with luciferin were performed as described previously.
ERK1/2, which was inhibited by a saturating concentration of AMD3100 [23]. Imaging data were quantified as fluorescence radiance or photon flux, respectively. Data for click beetle red luciferase complementation were normalized to total tumor burden assessed by fluorescence from eqFP650.

Statistics
Graphs and statistical analyses were prepared with GraphPad Prism. Cell culture studies were performed 3–5 times, while animal studies were performed twice. Data were plotted as mean values with standard error of the mean (SEM). Pairs of data were analyzed by Mann-Whitney U test to determine statistically significant differences. Kaplan-Meier survival curves were analyzed by Gehan-Breslow-Wilcoxon Test.

Results
Click beetle complementation reporter for interaction of CXCR4 and β-arrestin 2
CXCL12 binding to receptor CXCR4 results in activation of the cytosolic adapter protein β-arrestin 2 to the activated receptor. To image and quantify this key step in signal transduction, we used a recently described protein fragment complementation assay based on click beetle red luciferase [16]. In this system, CXCR4 is fused to the N-terminal fragment of click beetle luciferase (CXCR4-CBRN) and β-arrestin 2 to the C-terminal fragment of this enzyme (Ar-CBC) (Fig. 1B). Recruitment of β-arrestin 2 to CXCR4 also brings together luciferase fragments to produce bioluminescence as a quantitative measure of this protein interaction in CXCR4 signaling.

We transduced HeyA8 ovarian cancer cells with lentiviral vectors for CXCR4-CBRN and Ar-CBC. HeyA8-CXCR4-CBRN/Ar-CBC cells phosphorylated AKT in response to incubation with CXCL12 as determined by Western blotting, showing that these cells activated a known downstream effector of CXCR4-CBRN/Ar-CBC (Fig. 2A). As compared with parental HeyA8 cells, HeyA8-CXCR4-CBRN/Ar-CBC cells showed greater activation of AKT in response to CXCL12, consistent with transduction of additional functional CXCR4 into the imaging reporter cells. We also demonstrated that HeyA8-CXCR4-CBRN/Ar-CBC cells show time-dependent activation of kinases ERK1/2, which was inhibited by a saturating concentration of the CXCR4 inhibitor AMD3100 (Fig. 2B). HeyA8-CXCR4-CBRN/Ar-CBC cells overexpress β-arrestin 2-CBC relative to the endogenous protein as determined by Western blotting.

We used flow cytometry to assess cell surface expression of CXCR4 on HeyA8-CXCR4-CBRN/Ar-CBC cells, as well as parental HeyA8 cells and cells stably transduced with Gaussia luciferase (HeyA8-GL), CXCL12 fused to Gaussia luciferase (HeyA8-CXCL12-GL), or firefly luciferase and GFP (HeyA8-FL-GFP). All cells expressed similar levels of cell surface CXCR4 (Fig. 2C). Although transduced with CXCR4-CBRN, HeyA8-CXCR4-CBRN/Ar-CBC cells had levels of cell surface CXCR4 that were comparable to parental HeyA8 cells, likely because overexpression of β-arrestin 2 causes internalization of this receptor from the cell surface. [24,25].

CXCL12 drives complementation between CXCR4 and β-arrestin 2
To establish that bioluminescence from HeyA8-CXCR4-CBRN/Ar-CBC cells measures activation of CXCR4 signaling, we treated monolayer cultures of these cells with increasing concentrations of CXCL12 for 60 minutes. We treated parallel cultures of cells with an inhibitory concentration (1 μM) of the CXCR4 inhibitor AMD3100 or vehicle control during the incubation period [26] [27]. Treatment with CXCL12 produced a concentration-dependent increase in bioluminescence from association of CXCR4-CBRN and Ar-CBC, reaching peak 3-fold induction at 1 μg/ml CXCL12 (Fig. 3A). By comparison, cells treated with AMD3100 showed only basal bioluminescence with no response to CXCL12.

We also incubated HeyA8-CXCR4-CBRN/Ar-CBC cells with 100 ng/ml CXCL12 and 1 μM AMD3100 or vehicle control for increasing periods of time through 4 hours before measuring luciferase activity. Relative to untreated cells, cells incubated with 100 ng/ml CXCL12 and vehicle control showed time-dependent increases in bioluminescence, peaking at approximately 2-fold induction at 2 hours and then declining modestly (Fig. 3B). AMD3100 completely blocked effects of CXCL12 on bioluminescence complementation between CXCR4-CBRN and Ar-CBC. Collectively, these studies show that bioluminescence from HeyA8-CXCR4-CBRN/Ar-CBC cells responds to CXCL12 and establish that this reporter system can quantify inhibition of CXCL12-CXCR4 signaling.

Drug effects in spheroid culture
Recent studies suggest that spheroids and similar three-dimensional cell culture systems are more physiologic models of drug targeting and efficacy, due to factors including direct intercellular interactions and restricted diffusion of compounds [28,29]. In addition, ovarian cancer cells in patients form spheroids in ascites, posing a potential barrier to drug delivery [30]. To model the tumor microenvironment of ovarian cancer in vivo, we used spheroids of HeyA8-CXCR4-CBRN/Ar-CBC cells combined with equal numbers of HeyA8-CXCL12-GL cells, reproducing human ovarian cancer in which tumor cells secrete CXCL12 and/or express CXCR4. While parental HeyA8 cells do not express CXCL12 as determined by QRT-PCR (data not shown), HeyA8-CXCL12-GL cells secrete approximately 12 ng/ml CXCL12 in a 24 hour period, which is comparable to values reported for other ovarian cancer cells that secrete this chemokine endogenously [19] [31]. We treated spheroids with increasing concentrations of AMD3100 for 24 hours before quantifying bioluminescence. Relative to spheroids treated with vehicle control, AMD3100 inhibited bioluminescence from association of CXCR4-CBRN and Ar-CBC. Luciferase activity from the complementation reporter decreased by ~50% in spheroids treated with 1 μM AMD3100 (p<0.05) (Fig. 4A). We observed similar results when we extended incubations to two days with AMD3100 (data not shown). Inhibition of CXCR4, as quantified by the complementation assay, was less effective in spheroids as compared with monolayer culture, suggesting that three-dimensional architecture limits penetration of AMD3100 to all cells. However, we note that spheroid cultures test effects of chronic exposure to CXCL12 rather than acute addition of chemokine as done in two-dimensional culture, which also may contribute to differences in efficacy of AMD3100.

We tested protective effects of CXCL12 against cytotoxicity from cisplatin, a standard chemotherapeutic drug for ovarian cancer. For these assays, we used HeyA8-FL-GFP cells, which endogenously express CXCR4 [see Fig. 2C]. Firefly luciferase activity is directly proportional to numbers of tumor cells, providing a facile assay for cell viability in intact spheroids [32]. We generated spheroids combining HeyA8-FL-GFP cells with HeyA8-CXCL12-GL or HeyA8-GL cells, respectively, and then treated spheroids with increasing concentrations of cisplatin for 24 hours. In spheroids containing HeyA8-CXCL12-GL cells, HeyA8-FL-GFP cells were protected modestly against cytotoxic
effects of cisplatin, although only at 10 μM did we detect significant differences in cytotoxicity relative to spheroids containing HeyA8-GL cells (p < 0.05) (Fig. 4B). The extent of cytotoxicity was comparable following drug treatments for 48 hours (data not shown). These studies show that CXCL12 confers very modest protection against cisplatin in spheroids comprised solely of ovarian cancer cells.

**In vivo imaging of CXCR4 and β-arrestin 2 complementation in ovarian cancer**

We used a human tumor xenograft model of metastatic intraperitoneal ovarian cancer to determine to what extent complementation between CXCR4 and β-arrestin 2 detects CXCR4 activation and inhibition in vivo. We co-injected equal numbers of HeyA8-CXCR4-CBRN/Ar-CBC and HeyA8-CXCL12-GL cells intraperitoneally in mice and used bioluminescence imaging to quantify recruitment of β-arrestin 2 to CXCR4. Under baseline conditions, we readily observed bioluminescence from complementation between HeyA8-CXCR4-CBRN and Ar-CBC (Fig. 5A), indicating active CXCR4 signaling in malignant cells. We then randomly separated mice into groups treated for five days with either AMD3100 or vehicle control delivered from osmotic infusion pumps. There was no phenotypic evidence of toxicity in mice treated with AMD3100. Mice treated with AMD3100 had relatively less growth of ovarian cancer cells than animals receiving only vehicle control as quantified by fluorescence from far red fluorescent protein eqFP650 expressed in malignant cells (Fig. 5B) (p < 0.05). Using fluorescence from eqFP650 to normalize for differences in total numbers ovarian cancer cells, bioluminescence from interaction of CXCR4-CBRN with Ar-CBC was significantly lower in mice that received AMD3100 for five days as compared with vehicle control. Collectively, these data show the utility of this imaging system for measuring pharmacologic targeting of CXCL12-CXCR4 signaling and resultant effects of tumor growth in vivo (Fig. 5C) (p < 0.05).

**Combination therapy with AMD3100 and cisplatin reduces tumor burden**

We previously demonstrated that single agent therapy with AMD3100 alone modestly improves survival of mice with intraperitoneal disseminated ovarian cancer [14]. We hypothe-
sized that combined therapy with AMD3100 and a standard chemotherapeutic drug would significantly improve tumor control and survival, based on studies in leukemia showing that CXCL12 in the tumor microenvironment confers resistance to standard cytotoxic drugs [33]. To test this hypothesis, we implanted mice with HeyA8-CXCR4-CBRN/Ar-CBC and HeyA8-CXCL12-GL cells. One week after implanting tumors we randomized mice to four treatment groups: 1) vehicle control; 2) AMD3100 delivered by two-week osmotic infusion pumps; 3) cisplatin administered as 4 mg/kg i.p. every 5 days; and 4) combined AMD3100 and cisplatin. We continued cisplatin injections through the two-week delivery period of AMD3100 pumps and then discontinued all therapy.

We used bioluminescence from HeyA8-CXCR4-CBRN/Ar-CBC to analyze CXCR4 signaling in vivo and fluorescence imaging for eqFP650 to quantify tumor burden over time. We calculated area under the curve for bioluminescence and fluorescence and used ratios of these parameters to assess inhibition of CXCR4 over time (Fig. 6A). Mice treated with AMD3100 or the combination of AMD3100 and cisplatin had significantly lower bioluminescence from CXCR4-CBRN and Ar-CBC complementation relative to overall tumor burden, showing that this drug successfully blocks CXCR4 signaling in ovarian cancer cells in vivo (p<0.01).

Mice treated with single agent AMD3100 or cisplatin had modest, but significant, reductions in tumor burden measured by fluorescence imaging over the course of the experiment (Fig. 6B) (p<0.05). By comparison, combination therapy with both AMD3100 and cisplatin significantly reduced total numbers of HeyA8-CXCR4-CBRN/Ar-CBC cells relative to vehicle control or either drug alone (p<0.01 and p<0.05, respectively). These differences were evident even though mice received only two weeks of treatment with these drugs. Mice implanted with HeyA8 ovarian cancer cells developed ascites, but there was no difference in overall body weights among various treatment groups (data not shown). There was a trend toward enhanced survival in mice treated with both AMD3100 and cisplatin (Fig. 6C). However,
differences among AMD3100, cisplatin, and combined AMD3100 and cisplatin were not significant, although all treatments enhanced survival relative to vehicle control (p < 0.05).

**Discussion**

Ovarian cancer remains the leading cause of death from gynecologic malignancies with an overall five year survival of ≈50%. Poor prognosis of ovarian cancer is due in part to the fact that most patients present with advanced disease associated with intraperitoneal, liver, or systemic metastases [34]. Ovarian cancer initially is sensitive to chemotherapy with platinum-based drugs, although most patients relapse with drug-resistant tumor cells within approximately one year. These facts underscore the need for new treatment protocols and molecular targets to treat and eliminate ovarian cancer cells.

To facilitate development and optimization of CXCR4-targeted therapies in mouse models of ovarian cancer, we developed a click beetle luciferase complementation reporter for CXCR4 signaling. This reporter detects activation of CXCR4 based on recruitment of the cytosolic adapter protein, β-arrestin 2, to the ligand-bound receptor. Bioluminescence from the complementation reporter significantly increased in response to CXCL12, allowing us to use changes in light output as a quantitative measure of CXCR4 signaling and inhibition. Using this system, we measured pharmacodynamics of AMD3100 targeting CXCL12-CXCR4 in two- and three-dimensional cell-based assays and living mice with ovarian cancer. Comparing two-dimensional monolayer cultures and spheroids, we showed that inhibition of CXCL12-CXCR4 signaling with AMD3100, a clinically-approved small molecule, was less effective in three-dimensional culture. This result emphasizes known barriers to drug diffusion in spheroids and the utility of our CXCR4 signaling reporter to quantify pharmacodynamics of therapy in standard and advanced cell culture systems [35]. Two-dimensional cultures also test effects of AMD3100 to prevent activation of CXCR4 in response to acute addition of CXCL12, while spheroids quantify responses to AMD3100 in the context of ongoing, sustained CXCL12-CXCR4 signaling. Drug responses in spheroid cultures likely are more representative of treatment efficacy of AMD3100 in multicellular aggregates of ovarian cancer cells present in vivo.

By combining click beetle bioluminescence with whole animal fluorescence imaging, we were able to analyze changes in CXCR4 signaling relative to total tumor burden over extended periods of time in the same cohort of mice. The imaging reporter for CXCR4 activation in ovarian cancer complements our prior imaging system for directly quantifying CXCL12 binding to CXCR4 [14]. The advantage of the CXCR4-β-arrestin 2 reporter is that this system quantifies activation of CXCR4 in ovarian cancer cells by all sources of CXCL12 in the tumor microenvironment, while our previous assay detected only CXCL12 engineered with a fusion protein for complementation imaging. We readily detected bioluminescence from CXCR4-β-arrestin 2 complementation in 96 well plates (two-dimensional cultures) and 384 well plates (spheroids), suggesting the assay would be useful for

---

**Figure 5. Imaging association of CXCR4 and β-arrestin 2 in living mice.** A) Representative images of mice with intraperitoneal implants of HeyA8-CXCR4-CBRN/Ar-CBC and HeyA8-CXCL12-GL cells. Images were obtained before and following 5 days of treatment with osmotic pumps containing AMD3100 or vehicle control. Scale bar depicts ranges of photon flux values displayed on pseudocolor images. B) Fluorescence from ovarian cancer cells was measured in living mice treated with AMD3100 or vehicle control. Graph shows mean values + SEM for fluorescence relative to values measured on day 0 before beginning treatment. Arrows show the period when osmotic pumps were in place. C) Quantified photon flux data for click beetle red complementation in mice treated with AMD3100 or vehicle control, respectively. Data were normalized to tumor fluorescence for each mouse and graphed as mean values + SEM (n = 7 mice per group). *, p < 0.05. doi:10.1371/journal.pone.0051500.g005
high-throughput screening assays of potential CXCR4 inhibitors. The same cells could then be used to test compounds and dosing schedules in mouse models of ovarian cancer, using CXCR4-β-arrestin 2 complementation to quantify inhibition of the receptor and fluorescence to measure overall tumor burden. Collectively, our prior report and the current study establish imaging technologies to quantify key early steps in CXCL12-CXCR4 signaling and analyze targeting of therapeutic agents in pre-clinical models of ovarian cancer.

We demonstrated that combination therapy with AMD3100 targeting CXCL12-CXCR4 and the conventional drug cisplatin significantly reduced overall burden of ovarian cancer cells in the abdomen relative to treatment with either agent alone or vehicle control. These effects are consistent with prior reports in animal models of glioma and acute lymphoblastic leukemia in which responses to therapy were improved by treating mice with a standard chemotherapeutic drug and AMD3100 [36,37]. Although we noted a trend toward extended survival in mice treated with both cisplatin and AMD3100, differences in survival relative to mice treated with cisplatin or AMD3100 alone were not statistically significant. We administered drugs for only two weeks because of challenges in managing animal health over extended periods of chemotherapy, so we treated mice for less than half of the time following injection of cancer cells. Given more sophisticated methods to administer drugs and manage side effects of therapy in humans, we anticipate that patients with ovarian cancer could be treated with an inhibitor of CXCL12-CXCR4 and cisplatin for longer periods of time. Therefore, clinical benefits of targeting CXCR4 as part of combination therapy may be greater in patients with ovarian cancer.

In addition to direct effects on ovarian cancer cells, CXCL12 and CXCR4 regulate key components of the tumor microenvironment. CXCL12-CXCR4 signaling promotes tumor angiogenesis, and blocking this signaling pathway limits vascularization of tumor metastases in mouse models of ovarian cancer [10,38]. CXCL12 in the tumor microenvironment and ascites recruits several different types of immunoregulatory and immunosuppressive cells, including dendritic cells, T regulatory cells, and myeloid derived suppressor cells [8,11]. These cells limit immune surveillance and control of ovarian cancer cells, contributing to
References


